PRF Technologies (PRFX) COO lists vested and future option rights

Rhea-AI Filing Summary

PRF Technologies Ltd. filed a Form 3 for Chief Operating Officer Aviel Sigal, detailing existing employee stock option holdings over a total of 3,759 underlying ordinary shares. These options were granted under the 2019 PainReform Option Plan and are subject to Israeli Section 102 trustee arrangements.

Several grants are already fully vested, with grant dates on September 5, 2019, November 23, 2022, and October 10, 2024. A grant covering 3,000 underlying shares dated February 20, 2025 has 750 options vested at appointment, with the remaining 2,250 scheduled to vest in equal quarterly installments beginning on May 20, 2026, until fully vested on the three-year anniversary of the grant date, contingent on continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Aviel Sigal

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)(1)( 2)	--	--	--
holding	Employee Stock Option (Right to Buy)(1)( 2)	--	--	--
holding	Employee Stock Option (Right to Buy)(1)( 2)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 43 shares (Direct); Employee Stock Option (Right to Buy)(1)( 2) — 104 shares (Direct)

Footnotes (1)

1. Options granted under the 2019 PainReform Option Plan. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee. The grant date of this grant is September 5, 2019. This option grant is fully vested as of this date. The grant date of this grant is November 23, 2022. This option grant is fully vested as of this date. The grant date of this grant is October 10, 2024. This option grant is fully vested as of this date. The grant date of this grant is February 20, 2025. 750 of the options were vested as of the date of appointment. The remaining 2,250 options will vest in equal quarterly installments beginning on May 20, 2026 until fully vested on the three-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Aviel Sigal

(Last) (First) (Middle)

C/O PRF TECHNOLOGIES LTD.

65 YIGAL ALON ST.

(Street)

TEL AVIV 6744316

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PRF Technologies Ltd. [ PRFX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	(3)	09/05/2029	Ordinary Shares	43	$288	D
Employee Stock Option (Right to Buy)(1)( 2)	(4)	11/23/2032	Ordinary Shares	104	$684	D
Employee Stock Option (Right to Buy)(1)( 2)	(5)	10/10/2034	Ordinary Shares	612	$30	D
Employee Stock Option (Right to Buy)(1)( 2)	(6)	02/20/2035	Ordinary Shares	3,000	$15.75	D

Explanation of Responses:

1. Options granted under the 2019 PainReform Option Plan.

2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee.

3. The grant date of this grant is September 5, 2019. This option grant is fully vested as of this date.

4. The grant date of this grant is November 23, 2022. This option grant is fully vested as of this date.

5. The grant date of this grant is October 10, 2024. This option grant is fully vested as of this date.

6. The grant date of this grant is February 20, 2025. 750 of the options were vested as of the date of appointment. The remaining 2,250 options will vest in equal quarterly installments beginning on May 20, 2026 until fully vested on the three-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

	/s/ Sigal Aviel	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does PRF Technologies (PRFX) disclose in Aviel Sigal’s Form 3?

The Form 3 discloses Chief Operating Officer Aviel Sigal’s existing employee stock option holdings over 3,759 underlying ordinary shares. It lists exercise prices, expiration dates, grant dates, and vesting status for each option grant under the 2019 PainReform Option Plan.

How many PRF Technologies options does Aviel Sigal hold and on how many shares?

Aviel Sigal holds employee stock options linked to 3,759 underlying ordinary shares of PRF Technologies. The filing breaks this into separate grants, including 43, 104, 612, and 3,000 underlying shares, each with its own exercise price, expiration date, and vesting terms.

What are the key terms of Aviel Sigal’s largest PRFX option grant?

The largest grant covers 3,000 underlying ordinary shares with an exercise price of 15.7500 per share and an expiration date of February 20, 2035. Footnotes explain that 750 options vested at appointment and 2,250 will vest in equal quarterly installments, subject to continued service.

How is vesting structured for Aviel Sigal’s 3,000-share PRF Technologies option grant?

The 3,000-share grant dated February 20, 2025 has 750 options vested as of appointment. The remaining 2,250 options vest in equal quarterly installments starting May 20, 2026, and fully vest on the three-year anniversary of the grant date, contingent on continued service.

Are Aviel Sigal’s PRFX options held under a specific option plan or tax regime?

Yes. The options were granted under the 2019 PainReform Option Plan. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, the securities issued to the employee must be registered in the name of a trustee, as described in the footnotes.

Which PRF Technologies option grants for Aviel Sigal are already fully vested?

Option grants with grant dates of September 5, 2019, November 23, 2022, and October 10, 2024 are fully vested. Each corresponds to different exercise prices and underlying share amounts, reflecting prior compensation awards that have completed their vesting schedules.